Antonio Cubillo Gracián

3.9k citations

30 papers · 697 indexed · 1 hit paper · h-index 15

Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis 6
Oncology top 10%
- Colorectal Cancer Treatments and Studies 11
- Pancreatic and Hepatic Oncology Research 10
- Cancer Immunotherapy and Biomarkers 5
- Cancer Treatment and Pharmacology 5
- Cancer Cells and Metastasis 5
Pathology and Forensic Medicine top 10%
Cancer Research
- Cancer Genomics and Diagnostics 8
Immunology
Pulmonary and Respiratory Medicine
- Gastric Cancer Management and Outcomes 4

Co-authors: Armando Santoro Bruno Sangro Jaclyn Neely Ana Matilla Su Pin Choo Anthony B. El-Khoueiry Mirelis Acosta-Rivera Yun Shen
Cited by: Hepatology Oncology Pathology and Forensic Medicine
Journals: Journal of Clinical Oncology (12 papers)SHILAP Revista de lepidopterología (1 paper)Cancer Research (2 papers)
Partner nations: Spain United States Italy

In The Last Decade

Antonio Cubillo Gracián

29 papers receiving 690 citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Antonio Cubillo Gracián

Since Specialization

Citations

This map shows the geographic impact of Antonio Cubillo Gracián's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Cubillo Gracián with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Cubillo Gracián more than expected).

Fields of papers citing papers by Antonio Cubillo Gracián

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Cubillo Gracián. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Cubillo Gracián. The network helps show where Antonio Cubillo Gracián may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Antonio Cubillo Gracián, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Antonio Cubillo Gracián Line = papers co-authored together Antonio Cubillo Gracián links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study Journal for ImmunoTherapy of Cancer ·Michael J. Overman,Fabio Gelsomino,Massimo Aglietta,Mark Wong,María Luisa Limón Mirón,Gregory Leonard,Pilar García‐Alfonso,Andrew Hill,Antonio Cubillo Gracián,Eric Van Cutsem,Bassel F. El‐Rayes,Stephen McCraith,Beilei He,Ming Lei,Sara Lonardi	2024	24
2	1437P Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up Annals of Oncology ·Marcia Cruz‐Correa,D-Y. Oh,Ken Kato,Josep Tabernero,Yuxian Bai,Jingwen Shi,Kyung-Woo Lee,Hidekazu Hirano,David R. Spigel,Lucjan Wyrwicz,Roberto Pazo-Cid,Antonio Cubillo Gracián,L. Li,Y. Xu,Tao Sheng,Shu‐Hua Yang,R-H. Xu,Markus Moehler	2024	4
3	PANOVA-4 (EF-39): Pilot study of tumor treating fields (TTFields) therapy with atezolizumab, gemcitabine (GEM), and nab-paclitaxel (NabP) as first-line (1L) treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). Journal of Clinical Oncology ·Thomas Seufferlein,Antonio Cubillo Gracián,Marc Kueng	2024	1
4	Long-Term Survival in Hepatocellular Carcinoma following Second-Line Tumor Treating Fields Therapy and Sorafenib: A Case Report SHILAP Revista de lepidopterología ·Marisa Torres Velasco,Rafael Álvarez-Gallego,Paloma Peinado,Cesar Muñoz Gregorio,Lisardo Ugidos,Marcial García Morillo,Emilio Vicente,Yolanda Quijano,Susana Prados,Enrique de la Fuente,Antonio Cubillo Gracián	2024	0
5	Recommendations on the use of azole antifungals in hematology-oncology patients Revista Española de Quimioterapia ·José Ramón Azanza Perea,José Mensa,José Barberán,Lourdes Vázquez,Jaime Pérez de Oteyza,Mi Kwon,Lucrecia Yáñez,José María Aguado,Antonio Cubillo Gracián,Carlos Solano,Isabel Ruíz-Camps,Jesús Fortün,Miguel Salavert,Carlota Gudiol,Teresa Olave Rubio,Carolina García‐Vidal,Montserrat Rovira Tarrats,María Suárez-Lledó Grande,Pedro Antonio González Sierra,Carlos Dueñas Gutiérrez	2023	20
6	HEPANOVA: Final Efficacy and Safety Results from a Phase 2 Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Sorafenib in Advanced Hepatocellular Carcinoma (HCC) HPB ·E. Gkikka,Yann Touchefeu,T. Macarulla Mercadé,Antonio Cubillo Gracián,Th. Brunner,Maximilian Schultheiß,Monika Pazgan−Simon,T. Seufferlein,A.-L. Grosu	2022	1
7	Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial Journal of Clinical Oncology ·Thomas Yau,Vittorina Zagonel,Armando Santoro,Mirelis Acosta-Rivera,Su Pin Choo,Ana Matilla,Aiwu Ruth He,Antonio Cubillo Gracián,Anthony B. El-Khoueiry,Bruno Sangro,Tarek E. Eldawy,Jordi Bruix,Giovanni Luca Frassineti,Gina M. Vaccaro,Marina Tschaika,Christian Scheffold,Petra C. Koopmans,Jaclyn Neely,Fabio Piscaglia	2022	46
8	LBA25 FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer Annals of Oncology ·N.A. Dasari,Sara Lonardi,Rocio García‐Carbonero,M.E. Elez Fernandez,Takashi Yoshino,Alberto Sobrero,J.C. Yao,Pilar García‐Alfonso,Judit Kocsis,Antonio Cubillo Gracián,Andrea Sartore‐Bianchi,Takeshi Satoh,Violaine Randrian,Jiří Tomášek,Geoffrey Chong,Z. Yang,W. Schelman,M. Kania,Josep Tabernero,Cathy Eng	2022	20
9	CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosisbreakdown → Journal of Hepatology ·Masatoshi Kudo,Ana Matilla,Armando Santoro,Ignacio Melero,Antonio Cubillo Gracián,Mirelis Acosta-Rivera,Su Pin Choo,Anthony B. El-Khoueiry,Ryoko Kuromatsu,Bassel F. El‐Rayes,Kazushi Numata,Yoshito Itoh,Francesco Di Costanzo,Oxana Crysler,María Reig,Yun Shen,Jaclyn Neely,Marina Tschaika,Tami Wisniewski,Bruno Sangro	2021	141
10	Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE) Annals of Oncology ·Madappa N. Kundranda,Antonio Cubillo Gracián,Syed F. Zafar,E. Meiri,Johanna C. Bendell,Hana Algül,Fernando Rivera,Eugene R. Ahn,David Watkins,Uwe Pelzer,Veena Charu,Alena Zalutskaya,Geoffrey Kuesters,J. Marc Pipas,Sergio Santillana,Vasileios Askoxylakis,Andrew H. Ko	2020	42
11	Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens BMC Cancer ·Zev A. Wainberg,Kynan Feeney,Myung Ah Lee,Andrés J. Muñoz Martín,Antonio Cubillo Gracián,Sara Lonardi,Baek‐Yeol Ryoo,Annie Hung,Yong Lin,Johanna C. Bendell,J. Randolph Hecht	2020	21
12	Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC). Journal of Clinical Oncology ·Markus Moehler,Mikhail Dvorkin,Mustafa Özgüroğlu,Min‐Hee Ryu,Alina Muntean,Sara Lonardi,Marina Nechaeva,Arinilda Silva Campos Bragagnoli,Hasan Şenol Çoşkun,Antonio Cubillo Gracián,Toshimi Takano,Rachel Wong,Howard Safran,Gina M. Vaccaro,Narikazu Boku,Ilaria Conti,Janet Hong,Huiling Xiong,Julien Taı̈eb,Yung‐Jue Bang	2020	36
13	Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status. Journal of Clinical Oncology ·Masatoshi Kudo,Ana Matilla,Armando Santoro,Ignacio Melero,Antonio Cubillo Gracián,Mirelis Acosta-Rivera,Su Pin Choo,Anthony B. El-Khoueiry,Ryoko Kuromatsu,Bassel F. El‐Rayes,Kazushi Numata,Yoshito Itoh,Francesco Di Costanzo,Oxana Crysler,María Reig,Yun Shen,Jaclyn Neely,Christine Marie Dela Cruz,Carlos Baccan,Bruno Sangro	2019	79
14	A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer British Journal of Cancer ·Vera Gorbunova,J. Thaddeus Beck,Ralf‐Dieter Hofheinz,Pilar García‐Alfonso,Marina Nechaeva,Antonio Cubillo Gracián,László Mangel,Élena Elez,Dustin A. Deming,Ramesh K. Ramanathan,Alison Hewitt Torres,Danielle Sullivan,Yan Luo,Jordan Berlin	2018	47
15	YOSEMITE: A 3 arm double-blind randomized phase 2 study of gemcitabine, paclitaxel protein-bound particles for injectable suspension, and placebo (GAP) versus gemcitabine, paclitaxel protein-bound particles for injectable suspension and either 1 or 2 truncated courses of demcizumab (GAD) Annals of Oncology ·Antonio Cubillo Gracián,Andrew Dean,Andrés Muñoz,Manuel Hidalgo,Roberto Pazo-Cid,M. Martín,T. Macarulla Mercadé,Lara Lipton,Marion Harris,J.L. Manzano-Mozo,Joan Maurel,Carmen Guillén‐Ponce,N. C. Tebbutt,Prasad Cooray,Davendra Sohal,Mark M. Zalupski,Tatjana Kolevska,Robert Stagg,David Goldstein	2017	22
16	A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C Investigational New Drugs ·Khaldoun Almhanna,David Wright,T. Macarulla Mercadé,Jean‐Luc Van Laethem,Antonio Cubillo Gracián,Carmen Guillén‐Ponce,Jason E. Faris,Carolina Muriel López,Richard Hubner,Johanna C. Bendell,Alain Bols,Jaime Feliú,Naureen Starling,Peter C. Enzinger,Devalingham Mahalingham,Wells A. Messersmith,Huyuan Yang,Adedigbo A. Fasanmade,Hadi Danaee,Thea Kalebic	2017	31
17	Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C Investigational New Drugs ·Khaldoun Almhanna,María Luisa Limón Mirón,David Wright,Antonio Cubillo Gracián,Richard Hubner,Jean‐Luc Van Laethem,Carolina Muriel López,María Alsina,Frederico Longo Muñoz,Johanna C. Bendell,Irfan Firdaus,Wells A. Messersmith,Zhan Ye,Adedigbo A. Fasanmade,Hadi Danaee,Thea Kalebic	2017	20
18	A phase 1b study of the anticancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) with or without paclitaxel protein bound particles (nab-paclitaxel) in patients with pancreatic cancer. Journal of Clinical Oncology ·Antonio Cubillo Gracián,Michael B. Jameson,Enrique Grande,Prasad Cooray,Francis Parnis,Peter Grimison,Mark Jeffery,Robert Stagg,Jakob Dupont,Niall C. Tebbutt	2014	7
19	A blinded placebo (P)-controlled phase I/II dose-escalation study (DES) of brivanib (B), an oral selective dual inhibitor of FGF and VEGF signaling, in combination with cetuximab (C) and irinotecan (I) in patients (pts) with KRAS wild-type (KWT) advanced or metastatic colorectal cancer (amCRC): Safety, tolerability, and pharmacokinetics (PK) findings. Journal of Clinical Oncology ·Y. Park,Anthony B. El-Khoueiry,Antonio Cubillo Gracián,Per Pfeifer,Matías Chacón,D. Amadori,Tone Fokstuen,J. Chemidlin,Georgia Kollia,Dimitry S.A. Nuyten	2010	2
20	Erlotinib as a Single Agent in Select Subsets of Patients with Advanced Non–Small-Cell Lung Cancer Clinical Lung Cancer ·R.P. Carrion,Antonio Cubillo Gracián,Pedro Hernández	2007	4

About Antonio Cubillo Gracián

Antonio Cubillo Gracián is a scholar working on Oncology, Hepatology and Cancer Research, having authored 30 papers that have together received 697 indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (11 papers), Pancreatic and Hepatic Oncology Research (10 papers), Cancer Genomics and Diagnostics (8 papers), Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Cancer Immunotherapy and Biomarkers (5 papers), Cancer Treatment and Pharmacology (5 papers), Cancer Cells and Metastasis (5 papers) and Gastric Cancer Management and Outcomes (4 papers). The work is most often cited by research in Hepatology (308 citations), Oncology (439 citations) and Pathology and Forensic Medicine (119 citations). Antonio Cubillo Gracián has collaborated with scholars based in Spain, United States and Italy. Frequent co-authors include Armando Santoro, Bruno Sangro, Jaclyn Neely, Ana Matilla, Su Pin Choo, Anthony B. El-Khoueiry, Mirelis Acosta-Rivera, Yun Shen, Marina Tschaika and Bassel F. El‐Rayes. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact